PR Newswire · May 2026
The company said U.S. Patent No. 12,622,885 extends protection for a deuterated short-chain fatty acid class and supports NCE exclusivity through 2044.
Regulating the immune system to block cancer & autoimmune diseases
Company research
Public company, workplace, funding, and market signals
Overview
Clinical-stage biotechnology company developing oral deuterated short-chain fatty acid therapeutics that modulate the gut-immune axis, with SFA-002 as its lead candidate in psoriasis.
Primary product
SFA-002, an oral deuterated short-chain fatty acid therapeutic for psoriasis and other inflammatory/autoimmune diseases.
Founded
2016
Headquarters
Jenkintown, Pennsylvania, United States
Team size
1-10 employees
Industry
Biotechnology
Sub-industry
Clinical-stage biopharmaceuticals
Offices
610 Old York Road, Suite 400, Jenkintown, PA 19046
Philadelphia, PA
Business model
Drug discovery and clinical development
Platform licensing to pharma/biotech partners
License fees, royalties, and milestone payments
Funding
Stage
Clinical-stage
Total raised
$11.9M
Latest round
Bridge Financing · Nov 2023
Latest amount
$4.5M
People & investors
Leadership
CEO; Co-Founder
Chief Development Officer; Co-Founder
CSO; Co-Founder & Scientific Advisor
Chairman of the Board
COO and Senior Vice President, Development Operations
Chief Financial Officer; Board Director; Corporate Secretary
Work & culture
Product & market
Pricing
Not publicly disclosed; modeled around licensing, royalties, and milestone-based partnering rather than direct-to-consumer pricing.
Differentiators
- —Oral, once-daily dosing
- —Non-immunosuppressive immune tolerance approach
- —Gut-immune axis targeting
- —Deuterated SCFA-based new chemical entities
- —Potential disease-modifying rather than symptom-suppressing mechanism
- —Strong patent estate and NCE protection
- —Early human psoriasis data with promising safety and efficacy signals
Technology
Proprietary deuteration platform
Oral small-molecule biosynthetic compounds
Short-chain fatty acid (SCFA) chemistry
Gut-immune axis modulation
Target-specific adjuvants
Clinical trial development
Customers
Pharmaceutical and biotech partners
Patients with psoriasis
Patients with autoimmune disease
Patients with inflammatory liver disease / MASH / NASH
Patients with chronic inflammatory disease
Competitors
Existing psoriasis therapies such as etanercept
Existing psoriasis therapies such as apremilast
Existing topical steroid therapies such as betamethasone
Other oral immunomodulatory psoriasis therapies
Scale & contact
Estimated revenue
Under $1M
Latest news
PR Newswire · Mar 2025
SFA-002 met its safety endpoint, showed no treatment-related adverse events or rebound effects, and showed exploratory efficacy improvements on PASI and IGA.
PR Newswire · Mar 2025
The company presented preclinical head-to-head data showing SFA-002 activity in psoriasis models versus etanercept, apremilast, and betamethasone.
PR Newswire · May 2024
SFA Therapeutics completed enrollment of 15 patients in cohort 2 of its Phase 1b psoriasis study and said it expected to move toward Phase 2 development.
GlobeNewswire · Nov 2023
The company announced a $4.5 million bridge financing led by North South Ventures and reported updated Phase 1b psoriasis data and a foundational patent.
Jobs and careers at SFA Therapeutics
0 jobs at SFA Therapeutics
No open positions
Check back later for new openings